2020 China's top ten digestive tract clinical research released! New use of old medicine, jaundrel can prevent the recurrence of intestinal pneumoone

China's gastrointestinal tumor mortality rate is higher than in Europe and the United States, most patients are already in the middle and late stage of treatment, how to improve the rate of early diagnosis, and do a good job of standardized treatment? On the morning of November 7th, with the theme of "Truth-keeping, Innovation and the Future", the Sixth Hospital, affiliated with Sun Yat-sen University, held the 7th Guangzhou Digestive Disease Week, co-sponsored by the Gastroenterologists Branch of the Guangdong Physicians Association and the Southern Oncology Clinical Research Association of Guangdong Province (CSWOG).
20 sessions of the conference, inviting top experts and scholars at home and abroad to make a wonderful report on the latest developments in the field of digestion of internal and external science.
At the same time, the Conference also released the top ten clinical studies of the digestive tract in China in 2020, which conveys the important achievements made by Chinese scholars in the field of digestive tract research in the past year, so that domestic doctors can keep absoly informed of the frontiers of the subject area.
the selection is also to encourage doctors and scholars in the field of the digestive tract in China to carry out more rigorous design, the implementation of standardized clinical research.
(conference site), three research representatives shared their team's award-winning research at the Digestive Disease Week press release.
Chemotherapy combined target drug beva bead monoantin, can increase the surgical opportunities of patients with bowel cancer Fudan University affiliated Zhongshan Hospital Dr. Tang Wentao introduced the "Beval pearl single anti-combination FOLFOX6 compared to FOLFOX6 for Ras mutant non-removable colorectal cancer liver metastasis first-line treatment" research progress.
data show that about 50% of colorectal cancer patients will have liver metastasis during the course of the disease, liver metastasis is also the main cause of death.
for patients with liver metastasis, only 10% to 20% of patients have a chance of surgical removal, and the vast majority of patients have an inability to operate on their livers.
", if only for medication, their five-year survival rate is very low, basically less than 5%.
" Tang Wentao said that if the conversion treatment, so that the tumor shrinks after surgery, the patient's five-year survival rate will be increased from 5% to more than 30%.
, the team conducted translational therapy studies in patients with hepatic metastasis in Ras mutated colorectal cancer.
study included 241 patients aged 18-75 with liver metastasis of all-Ras mutant colorectal cancer, of whom 121 were treated with a combination of chemotherapy-targeted drug beva bead monotherapy and others with standard two-drug chemotherapy.
compared, patients with the standard two-drug chemotherapy program had a liver conversion excision rate of only 5%, i.e. only 5% of patients were able to get a liver removal.
And after the addition of beva bead monoantin in standard chemotherapy, the patient's liver conversion excision rate increased to 22%, the medium PFS (no progression lifetime) increased from 6 months to 9.5 months, and the medium OS (survival) increased from 20.5 months to 25 months.
old medicine is new! The treatment of diarrhea, but also to prevent adenoma polyps Shanghai Jiaoda University School of Medicine affiliated Renji Hospital digestive medicine Dr. Zhai Tianhui shared the "small pyridine contrast placebo for the prevention of recurrence of colorectal adenoma", multi-center randomized double-blind placebo controlled clinical trial.
incidence of colorectal cancer ranks third in China's malignant tumor list, 95% of bowel cancer is evolved from adenoma-like psychics.
said, "Early through the gooscope can be early diagnosis and treatment, timely removal of adenoma-like blood, can reduce the incidence and mortality of colorectal cancer."
, however, the recurrence rate of adenoma-like veocarcinoma in the intestines is high, with nearly half of patients returning within three years of removal.
" how to reduce the recurrence rate of intestinal adenoma-like psychics has become a concern of experts and scholars in the field of digestive diseases.
Previous studies have focused on folic acid, aspirin, metformin, and the research team in which Ni Tianhui is located has focused on the treatment of infectious enteritis commonly used drugs, traditional Chinese medicine hydrochloric acid small pyridine (also known as jaundial).
Tianhui introduced, in recent years, the research on jaundial has been increasing, according to existing research tips, the drug can not only effectively treat diarrhea, but also antioxidant, blood lipid, blood sugar, and even anti-tumor effect.
" cell experimental study confirmed that jaundial has the effect of regulating tumors and inhibiting the proliferation of colorectal cells in the body.
" In order to find out the role of jaundol in colorectal tumor prevention, the research team from 2014 in Beijing, Shanghai, Guangdong, Jiangsu, Fujian, Tianjin six provinces and cities, after screening into the multi-center 1108 patients with colorectal adenoma, found that the application of jaundia, after surgery to prevent recurrence of colorectal adenoma has a significant effect, compared to the placebo group patients relapsed rate decreased by 23%.
" jaundate throughout the study period of good efficacy, high safety, fewer side effects, the price is also very affordable, the liver and kidneys are not too burden, there are clinical studies confirmed that jaundia also has a certain liver protection effect.
" Zhai Tianhui said that, for the time being, jaundina is very suitable as a preventive drug after adenoma-like psychic surgery.
more research evidence on whether the drug can be used as a first- or second-line prevention drug for bowel cancer.
The introduction of "helpers" in gastric cancer surgery can identify more lymph nodes to improve the prognostication of patients affiliated with Concord Hospital of Fujian Medical University, dr.
gastric cancer ranks among the top three malignant tumors in China, with about 500,000 new gastric cancer patients diagnosed each year, accounting for 40%-50% of the total number of gastric cancer patients worldwide.
compared with other countries, the majority of gastric cancer patients in China are diagnosed in the middle and late stage, surgery is the main treatment method for patients with middle and late stage gastric cancer.
Love said, "In addition to gastric primary lesions, patients with advanced gastric cancer also need to clean the surrounding lymph nodes, the introduction of fluorescent navigation technology in surgery can help doctors identify the possible metastasis of small lymph nodes or lymphatic lesions, improve the number of cleaning of lymph nodes, improve patient prognosis."
" fluorescent navigation technology, mostly used in liver and bile surgery, this application in gastrointestinal tumors is a new attempt.
the technique is used to inject a developmental agent into a patient with stomach cancer, as if a "navigator" had been put on the surrounding lymph nodes to give it a blue or purple fluorescent dot that appeared before the doctor's eyes.
is not yet able to accurately identify the lymph nodes with cancer cell metastasis, then the number of lymph nodes swept in gastric cancer surgery, directly reflects the quality of the operation.
, the more lymph nodes are cleaned, the better the patient's prognostication.
study found that fluorescent navigation technology increased the number of lymph nodes cleaned by 20 percent, while reducing lymph node cleaning incompletely by 26 percent.
" love said that as to whether to improve the long-term survival rate of patients with advanced gastric cancer, it is uncertain, the research team will be followed up for up to five years.
(Communicator Jane Young Daisian) 2020 "Top 10 Clinical Research in the Digestive Tract Field" list (ranked in no order) as follows: 1. Sanyo vs. the prospective randomized study communication Chen Haiquan Fudan University Affiliated Oncology Hospital First Li Bin Fudan University Affiliated Oncology Hospital 2. Laparoscopic comparison of abdominal total gastric excision treatment clinical I. stage gastric cancer safety: CLASS-02 Multi-center prospective randomized control study communication Sun Yihong The application of lymph node cleaning in laparoscopic root-and-cure gastric excision: random clinical research communication Huang Changming, Zheng Chaohui Fujian Medical University, First Liu Fenglin, Fudan University-affiliated Zhongshan Hospital, Fudan University Affiliated Concord Hospital First Chen Qiyue, Love Fujian Medical University Affiliated Concord Hospital 4. Full laparoscopic Uncut Roux-en-Y matching application to root-and-treat far-end gastric excision: mid-term analysis of the multi-center randomized controlled study communication season Air Force Military Medical University Xijing Hospital First Wang Wei Air Force Military Medical University Xijing Hospital 5.Karelli Zhu single anti-contrast researchers selected chemotherapy for second-line treatment of local late stage / metastatic esophageal squamous cancer (ESCORT): multi-center random open Phase III research communication Xu Jian Ming PLA General Hospital 5th Medical Center First Yellow Mirror Medical College Oncology Hospital First Chen Wei Shanghai Cancer Center 6. Low-dose metformin heavy programming esophageal cancer immunological microencea: Phase II Clinical Research Newsletter Zhang Wei, First Wang Hong, School of Medicine, Jinan University Yuxuan, Lin Yuxuan, Jinan University School of Medicine 7. Beval Pearl single anti-joint FOLFOX6 compared to FOLFOX6 for Ras mutant non-removable colorectal cancer liver metastasis first-line treatment: BECOME random control study communication Xu Jianmin Fudan University affiliated Zhongshan Hospital First Tang Wentao Fudan University Affiliated Zhongshan Hospital 8. Small pyridine contrast placebo for the prevention of recurrence of colorectal adenoma: multi-center double-blind randomized control study communication room Jingyuan first Chen Wei, Gao Qinxuan, Yan Tianhui Shanghai Jiaodian University School of Medicine affiliated Renji Hospital 9. Physiological saline injection under mucous membrane combined endoscopic ultrasound compared to simple endoscopic ultrasound on T1a and T1b esophageal cancer identification communication Li Jianjun, Xu Guoliang Sun Yat-sen University affiliated oncology hospital first Helongjun Sun Yat-sen University affiliated oncology hospital 10. Computer-aided diagnostic AI system applied to colonoscopy process adenoma detection (CADe-DB test): double-blind study Communication Zhou Guanyu Sichuan Provincial People's Hospital First Wang Wei Sichuan Provincial People's Hospital 39 Health Network Source: 39 Health Network Copyright Notice: All text, pictures and audio and video materials marked "Source: Meis Medicine" or "Source: MedSci Original" are owned by Meis Medical, without authorization, no media, website or individual shall be reproduced, and shall be authorized to reproduce with the words "Source: Meis Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here